Covid19 Clinical Trial
Official title:
Respiratory Muscle Function, Dyspnea, Exercise Capacity and Quality of Life in Severe COVID19 Patients After ICU Discharge: a 6 Months Follow-up Observational Study
| NCT number | NCT04853940 |
| Other study ID # | 419/20 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 1, 2021 |
| Est. completion date | January 1, 2022 |
Further knowledge regarding sequelae in severe COVID-19 patients who have required ICU admission for invasive mechanical ventilation is still needed. Available evidence suggests ongoing respiratory impairment and impact in quality of life.
| Status | Completed |
| Enrollment | 50 |
| Est. completion date | January 1, 2022 |
| Est. primary completion date | November 30, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - ?18 years old, - subjects diagnosed with COVID-19 confirmed by positive SARS-CoV-2 PCR testing who require admission to ICU for invasive mechanical ventilation - invasive ventilation > 24 hours. Exclusion Criteria: - pre-existing cognitive impairment, - communication/language barrier - any concurrent physical or mental health condition/ impairment that prevents subjects from taking part in evaluations or providing informed consent - loss of independent walking ability (with or without walking aids) prior to hospitalisation defined by a score of =2 on the mobility item of the modified Barthel Index, - pregnancy, - any injuries/surgery that requires medical bed rest. |
| Country | Name | City | State |
|---|---|---|---|
| Spain | ICU. Ramón y Cajal University Hospital | Madrid |
| Lead Sponsor | Collaborator |
|---|---|
| Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Maximal Inspiratory Pressure (MIP) (centimetres of water, cmH20) | It is the greater pressure which may be generated during maximal inspiration by the inspiratory muscles. | < 3 months after ICU discharge | |
| Primary | Maximal Inspiratory Pressure (MIP) (centimetres of water, cmH20) | It is the greater pressure which may be generated during maximal inspiration by the inspiratory muscles. | within 6 months after ICU discharge | |
| Secondary | Diaphragm Thickening Ratio during deep breathing (centimetres) | B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio during deep breathing. Diaphragm Thickening Ratio = Diaphragm Thickness at Functional Residual Capacity/ Diaphragm thickness at Total Lung Capacity. | within 3 months after ICU discharge | |
| Secondary | Diaphragm Thickening Ratio during deep breathing (centimetres) | B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio during deep breathing. Diaphragm Thickening Ratio = Diaphragm Thickness at Functional Residual Capacity/ Diaphragm thickness at Total Lung Capacity. | within 6 months after ICU discharge | |
| Secondary | Diaphragm Thickening Ratio during quiet breathing (centimetres) | B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio at Tidal Volume. Diaphragm Thickening Ratio = Diaphragm Thickness at the end of a quiet expiration/ Diaphragm thickness at the end of a quiet inspiration. | within 3 months after ICU discharge | |
| Secondary | Diaphragm Thickening Ratio during quiet breathing (centimetres) | B-mode Diaphragm ultrasound will be performed to measure diaphragm thickening ratio at Tidal Volume. Diaphragm Thickening Ratio = Diaphragm Thickness at the end of a quiet expiration/ Diaphragm thickness at the end of a quiet inspiration. | within 6 months after ICU discharge | |
| Secondary | Diaphragm Excursion during deep breathing (centimetres) | M-mode Diaphragm Ultrasound imaging will be performed to measure diaphragm excursion during deep breathing defined as the displacement (centimetres) of the diaphragm between Functional Residual Capacity and Total Lung Capacity | within 3 months after ICU discharge | |
| Secondary | Diaphragm Excursion during deep breathing (centimetres) | M-mode Diaphragm Ultrasound imaging will be performed to measure diaphragm excursion during deep breathing defined as the displacement (centimetres) of the diaphragm between Functional Residual Capacity and Total Lung Capacity. | within 6 months after ICU discharge | |
| Secondary | Maximal Expiratory Pressure (MEP) (cmH20) | It is the greater pressure which may be generated during maximal expiration by the inspiratory muscles. | within 3 months after ICU discharge | |
| Secondary | Maximal Expiratory Pressure (MEP) (cmH20) | It is the greater pressure which may be generated during maximal expiration by the inspiratory muscles. | within 6 months after ICU discharge | |
| Secondary | Modified Medical Research Council (mMRC) Dyspnea score | Dyspnea will be measured with the mMRC Dyspnea scale (range: 0-4, higher values indicating higher level of dyspnea) | within 3 months following ICU discharge | |
| Secondary | Modified Medical Research Council (mMRC) Dyspnea score | Dyspnea will be measured with the mMRC Dyspnea scale (range: 0-4, higher values indicating higher level of dyspnea) | within 6 months following ICU discharge | |
| Secondary | 6-Minutes Walk Test (6MWT) (metres) | The 6MWT will be used to measure exercise capacity | within 3 months following ICU discharge | |
| Secondary | 6-Minutes Walk Test (6MWT) (metres) | The 6MWT will be used to measure exercise capacity | within 6 months following ICU discharge | |
| Secondary | Saint George's Respiratory Questionnaire (SGRQ) score | The SGRQ is used to measure health-related quality of life (range: 0-100, higher scores represent higher impairment in quality of life) | within 3 months following ICU dischargemonths following ICU discharge | |
| Secondary | Saint George's Respiratory Questionnaire (SGRQ) score | The SGRQ is used to measure health-related quality of life (range: 0-100, higher scores represent higher impairment in quality of life) | within 6 months following ICU dischargemonths following ICU discharge |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |